213 related articles for article (PubMed ID: 33711241)
1. Novel synthetic drugs for the treatment of non-Hodgkin lymphoma.
Manji F; Puckrin R; Stewart DA
Expert Opin Pharmacother; 2021 Aug; 22(11):1417-1427. PubMed ID: 33711241
[No Abstract] [Full Text] [Related]
2. Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
Rodgers TD; Reagan PM
Expert Opin Emerg Drugs; 2018 Jun; 23(2):111-122. PubMed ID: 29781323
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
4. New drugs for the treatment of non-Hodgkin lymphomas.
Smith SM
Chin Clin Oncol; 2015 Mar; 4(1):14. PubMed ID: 25841721
[TBL] [Abstract][Full Text] [Related]
5. Targeting indolent non-Hodgkin lymphoma.
Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
[TBL] [Abstract][Full Text] [Related]
6. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.
Siddiqi T; Rosen ST
Oncology (Williston Park); 2015 Apr; 29(4):299-308. PubMed ID: 25920929
[TBL] [Abstract][Full Text] [Related]
7. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
8. Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done?
Witkowska M; Smolewski P; Majchrzak A; Robak T
Expert Opin Drug Discov; 2016 Nov; 11(11):1033-1045. PubMed ID: 27569454
[TBL] [Abstract][Full Text] [Related]
9. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Apuri S; Sokol L
Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
[TBL] [Abstract][Full Text] [Related]
10. Next Generation of Targeted Molecules for Non-Hodgkin Lymphomas: Small-Molecule Inhibitors of Intracellular Targets and Signaling Pathways.
Choe H; Ruan J
Oncology (Williston Park); 2016 Sep; 30(9):847-58. PubMed ID: 27633417
[TBL] [Abstract][Full Text] [Related]
11. Breakthrough therapies in B-cell non-Hodgkin lymphoma.
Cheah CY; Fowler NH; Wang ML
Ann Oncol; 2016 May; 27(5):778-87. PubMed ID: 26802148
[TBL] [Abstract][Full Text] [Related]
12. Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
Barth MJ; Minard-Colin V
Br J Haematol; 2019 Jun; 185(6):1111-1124. PubMed ID: 30701541
[TBL] [Abstract][Full Text] [Related]
13. New targeted therapies for malignant lymphoma based on molecular heterogeneity.
Horn H; Staiger AM; Ott G
Expert Rev Hematol; 2017 Jan; 10(1):39-51. PubMed ID: 27918211
[TBL] [Abstract][Full Text] [Related]
14. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
Kubuschok B; Trepel M
Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
[TBL] [Abstract][Full Text] [Related]
15. Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds.
Cox MC; Bocci G
Cancer Lett; 2022 Jan; 524():144-150. PubMed ID: 34673128
[TBL] [Abstract][Full Text] [Related]
16. Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.
Jahangiri S; Friedberg J; Barr P
Expert Opin Emerg Drugs; 2014 Sep; 19(3):367-83. PubMed ID: 24960458
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
[TBL] [Abstract][Full Text] [Related]
18. Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.
Rosenthal A
Curr Hematol Malig Rep; 2017 Jun; 12(3):207-216. PubMed ID: 28439761
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapies for B-cell non-Hodgkin lymphoma.
Briones J
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1305-16. PubMed ID: 19761434
[TBL] [Abstract][Full Text] [Related]
20. Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.
Boyle EM; Morschhauser F
Expert Opin Drug Saf; 2015 Apr; 14(4):601-7. PubMed ID: 25716061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
